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Abstract 
 
Background: Major depressive disorder (MDD) has a high personal and socio-economic 
burden and N60% of patients fail to achieve remission with the ﬁrst antidepressant. The 
biological mechanisms behind antidepressant response are only partially known but genetic 
factors play a relevant role. A combined predictor across genetic variants may be useful to 
investigate this complex trait. 
Methods: Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) 
antidepressant efﬁcacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and 
tested whether these predicted symptom improvement or remission from the GENDEP 
study (n = 736) to the STAR*D study (n = 1409) and vice-versa, including the whole sample 
or only patients treated with escitalopram or citalopram. Using summary statistics from 
Psychiatric Genomics Consortium for MDD and schizophrenia, we tested whether PRS from 
these disorders predicted symptom improvement in GENDEP, STAR*D, and ﬁve further 
studies (n =3756). 
Results: No signiﬁcant prediction of antidepressant efﬁcacy was obtained from PRS in 
GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence 
of overlap in the genetics of antidepressant response with either MDD or schizophrenia, 
either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the 
results. 
Discussion: We identiﬁed no signiﬁcant predictive effect using PRS between 
pharmacogenetic studies. The genet-ic liability to MDD or schizophrenia did not predict 
response to antidepressants, suggesting differences between the genetic component of 
depression and treatment response. Larger or more homogeneous studies will be necessary 
to obtain a polygenic predictor of antidepressant response. 
 
1. Introduction 
Major depressive disorder (MDD) is a common mental disorder characterized by sadness, 
anhedonia, guilt, feelings of low self-worth, poor concentration, disturbed appetite and 
sleep and suicidal thoughts (World Health Organization, 1993; American Psychiatric 
Association, 2013). Its heavy socio-economic and individual burden makes it a global 
concern: lifetime prevalence of MDD ranges from 10% to 15% and MDD is one of the top 
ten causes of years lived with disability (YLDs) world-wide (The WHO World Mental Health 
Survey Consortium, 2004; Global Burden of Disease Study 2013 Collaborators, 2015). 
Antidepressant drugs are the ﬁrst-line treatment for MDD, with N30 antidepressant drugs 
available (Fabbri et al., 2016). Responses vary widely across individuals: one third of patients 
show complete remission after the ﬁrst drug prescribed, one third improves after a change 
of treatment or augmentation, and one third fail to respond after two different 
antidepressants prescribed (Trivedi et al., 2006; Souery et al., 2011). For each patient, the 
most effective treatment can only be identiﬁed by trial and error - a lengthy process which 
delays recovery and leads to poorer clinical outcomes (Steimer et al., 2001). The ability to 
identify the most effective drugs for each patient or to predict treatment resistance would 
be a turning point in MDD treatment, enabling personalized prescribing. However, no 
predictor of antidepressant response is currently available; clinical characteristics are weak 
predictors of improvement in depressive symptoms, and no established biomarkers or 
genetic signatures exist for antidepressant response. 
Genome-wide association studies (GWAS) to identify single nucleotide polymorphisms 
(SNPs) associated with antidepressant response have provided tentative hints, but most 
associations have been inconclusive and are unreplicated (Myung et al., 2015; Sasayama et 
al., 2013; Biernacka et al., 2015; GENDEP Investigators, MARS Investigators and STAR฀D 
Investigators, 2013; Uher et al., 2010; Trivedi et al., 2006; Ising et al., 2009). These 
disappointing ﬁndings may be ascribed to several features of pharmacogenetic studies: 
limited sample size, heterogeneity be-tween studies in design, drug, and assessment of 
outcome. Given the challenges of accruing sufﬁciently strong evidence to conﬁrm 
association of a single SNP with antidepressant response, an alternative approach is to 
construct a single summary genetic variable representing genome-wide information which 
can be used for prediction. 
Polygenic risk scores (PRS) capture in a single variable the additive effect of SNP alleles 
across the genome (Dudbridge, 2013). In contrast to GWAS analysis, where a single SNP 
must reach stringent signiﬁcance levels, PRS are constructed from multiple SNPs with lower 
evidence of association, with the assumption that genetic markers that do not meet the 
genome-wide signiﬁcance threshold might have good predictive power when they are 
considered collectively. 
In this study we test whether polygenic risk scores can provide pre-diction of response to 
anti-depressants, building PRS directly from clin-ical trials of antidepressant response 
(STAR*D, GENDEP) (Garriock et al., 2010; Uher et al., 2010), and secondly testing the 
hypothesis of whethergenetic liability to the psychiatric disorders of MDD and schizophrenia 
contributes to variation in antidepressant response. Indeed an overlap between the 
genetics of MDD and antidepressant response has been hypothesized, but MDD also shares 
susceptibility genetic factors with schizophrenia (Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013), suggesting a possible overlap between the genetics of 
schizophrenia and antidepressant response. We analyse two large pharmacogenetic trials 
(GENDEP, STAR*D) and expand our study to other studies of antidepressant response, giving 
a substantial sample size in which to develop and test predictors of treatment response. 
2. Materials and methods 
2.1. Pharmacogenetic studies 
Seven pharmacogenetic studies were included, all similar in their fundamental features: (1) 
participants were treatment-seeking individuals diagnosed with MDD based on DSM-IV/ICD-
10 criteria (World Health Organization, 1993; American Psychiatric Association, 2013), with 
other psychiatric diagnoses excluded (schizophrenia spectrum disorders, bipolar disorders, 
current alcohol or drug dependence). For each study participant, prospective data on 
outcome of antidepressant treatment were recorded according to standard and comparable 
scales. Missing end-point measurements were imputed using the best unbiased estimate 
from a mixed-effect linear regression model, with ﬁxed linear and quadratic effects of time 
and random effects of individual and centre of recruitment (for multi-centric studies) 
according to previous studies (Tansey et al., 2012; Uher et al., 2010). Patients were included 
in the analyses only if baseline assessment and at least one post-baseline assessment were 
available. 
The GENDEP and STAR*D studies formed our primary studies for discovery and testing 
variants speciﬁc to antidepressant response. For testing the hypothesis that genetic liability 
for MDD and schizophrenia predicts antidepressant response, we included four further trials 
from the NEWMEDS consortium (GENPOD, GODS, GSK, Pﬁzer) (Tansey et al., 2012) and a 
newly genotyped naturalistic study from the University of Muenster (Baune et al., 2008, 
2010). All studies were approved by local ethics boards of participating centres, and all 
participants provided written informed consent after the study procedures were explained 
and prior to sample collection. Detailed information for each sample are given in Table 1 
and Supplementary Methods. 
2.2. Outcome measures 
Two phenotypes were investigated at the end-point of each study, a continuous measure of 
improvement, calculated as the percentage change in symptom score, and symptom 
remission (Table 1). Percent-age change was preferred to absolute change because it is less 
correlated with initial severity, relatively independent of the scale, and closely reﬂects 
clinician's impression of improvement (Uher et al., 2009; Lane, 2008; Mallinckrodt, Clark and 
David, 2001). Remission was deﬁned as a score below a consensus cut-off that corresponds 
to absence of depression for each scale (Hamilton, 1967; Montgomery and Asberg, 1979; 
Beck et al., 1961). For GENDEP, remission was deﬁned using HAMD-17, since there was 
stronger consensus about the threshold to identify remission on this scale compared to 
MADRS (Uher et al., 2008). Remission has lower power to detect an effect than a continuous 
measure (Streiner, 2002) but it may be associated with MDD prognosis (Gaynes et al., 2009). 
 
 
 
 
2.3. Psychiatric Genomics Consortium summary statistics 
Genome-wide summary statistics for large meta-analysis from the Psychiatric Genomics 
Consortium (PGC) were used to construct PRS for MDD and schizophrenia for each 
participant in the pharmacogenomic studies. Summary statistics for schizophrenia were 
downloaded from pgc.unc.edu (36,989 schizophrenia cases, 113,075 controls) (Ripke et al., 
2014). MDD summary statistics were from the latest PGC MDD meta-analysis comprising 
51,865 MDD cases and 112,200 controls (unpublished data). 
2.4. Statistical analysis 
Individual-level genotypes were available for all pharmacogenetic studies. GENDEP and 
STAR*D were imputed using genotype data from genome-wide and exome arrays capturing 
both common and rare variation (Table 1; Supplementary Methods). The Muenster study 
was imputed from Inﬁnium PsychArray-24, and phenotype and genotype data from studies 
in the NEWMEDS consortium (GENPOD, Pﬁzer, GSK, GODS) were used as previously 
reported (Tansey et al., 2012). All these studies were imputed using Minimac3 and the 
Haplotype Reference Consortium (HRC version 1) as reference panel. In STAR*D and 
GENDEP, tests of SNP association were performed using linear regression (for percentage 
change in symptom score) and logistic regression (remission) using PLINK (Purcell et al., 
2007). Each model included co-variates of ancestry-informative principal components (PCs), 
age, base-line severity of depression and ascertainment centre (for multi-centre studies of 
STAR*D, GENDEP and Pﬁzer). The number of ancestry-informative PCs used for each sample 
is speciﬁed in Supplementary Methods and the ﬁrst two PCs for each sample are plotted in 
Supplementary Fig. 1. 
GWAS summary data from GENDEP, STAR*D, PGC-SCZ, and PGC-MDD were used as 
discovery studies. A schematic representation of study design is provided in Fig. 1. SNPs 
were clumped by linkage dis-equilibrium (LD) and p-value: SNP with the smallest p-value 
within a 250 Kb window were retained, and all SNPs in LD (r2 N 0.1) with the retained SNP 
were excluded. When PGC-MDD was used as discovery study, markers with allele frequency 
difference of over 0.15 between discovery and test data sets were excluded to ensure 
comparability given the different genotyping chips and imputation reference panels used. 
PRS were constructed using the software PRSice v.1.25 (Euesden, Lewis and O′Reilly, 2015). 
PRS were calculated as the sum of associated alleles, weighted by effect sizes, for SNPs with 
p-values less than pre-deﬁned threshold PT.Nine p-value thresholds of PT b (0.0001, 0.001, 
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1) were used with all pruned SNPs included in the ﬁnal threshold 
PT =1.Symptomimprove-ment and remission outcomes were regressed on polygenic scores, 
adjusting for the covariates as used in the GWAS analyses, and com-pared to a model 
including only covariates. The proportion of phenotypic variance explained by PRS was 
assessed by R2 (for improvement) or Nagelkerke's R2 (for remission). To decrease 
pharmacological heterogeneity across samples and to increase power, analyses were 
repeated stratifying by antidepressant, including only studies using escitalopram and 
citalopram (STAR*D, GSK, 417 GENDEP participants, 242 GENPOD participants and 121 
Muenster participants). 
Prediction of improvement from MDD and schizophrenia was implemented separately in 
each pharmacogenetic study, then a ﬁxed effects meta-analysis was performed to combine 
results across studies at each PT.The useofaﬁxed effect approach was in line with previous 
meta-analyses in the ﬁeld (e.g. GENDEP Investigators, MARS Investigators and STAR฀D 
Investigators, 2013). 
A Bonferroni correction was applied to account for multiple test-ing. We estimated p = 0.01 
as an approximate correction for correlation between PRS at 9 PT values, and then 
corrected further for four independent hypotheses, giving a required signiﬁcance level of p = 
0.0025. 
 
 
 
 
Fig. 1. Study design, capturing (1) prediction of improvement and remission using large 
antidepressant response trials as discovery studies, and (2) prediction from psychiatric 
disorder PRS, into all antidepressant studies. Arrows indicate PRS from discovery to test 
data sets. PGC = Psychiatric Genomics Consortium. 
 
2.5. Power calculation 
Power calculations for the polygenic analysis were performed using the R package 
AVENGEME (Palla and Dudbridge, 2015), at each PT. Models assumed SNP heritability of 
0.21 for MDD (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013), 
0.42 for response to antidepressants (Tansey et al., 2013) and 0.33 for schizophrenia (Ripke 
et al., 2013a). Lifetime prevalences used were 16.2% for MDD (Kessler et al., 2003), and 
0.87% for schizophrenia (Perälä et al., 2007). The models used for power calculation 
assumed that the markers are in-dependent and 5% of SNPs have an effect in the training 
phenotype. For cross-trait polygenic analysis (MDD, schizophrenia and antidepressant 
response), two hypothetical scenarios were tested, comparing change in prediction accuracy 
when covariance between genetic effects in the training and target samples were 25% or 
50%. 
With GENDEP or STAR*D as discovery sample, the power to detect the genetic contribution 
of response to antidepressants was limited (12% for improvement, 8% for remission). Using 
PGC MDD and PGC SCZ as discovery had higher power. Assuming a covariance of 25% be-
tween SCZ and improvement in depression symptoms gave N90%power in the combined 
pharmacogenetic samples. A covariance of 50% between MDD and improvement in 
depression symptoms had 90% power to detect an effect in the combined pharmacogenetic 
sample, but only power of 37% with 25% covariance. 
 
3. Results 
Firstly, we tested whether PRS predict improvement and remission in depression symptoms 
after twelve weeks of antidepressant treatment, using GENDEP and STAR*D. Each study was 
used as discovery and then as target study, testing the PRS constructed from STAR*D GWAS 
results in GENDEP, and vice-versa. No signiﬁcant prediction of treatment response was 
attained for improvement or for remission in the whole sample (Supplementary Fig. 2) or 
restricting the analysis to citalopram/escitalopram (Supplementary Fig. 3) treated patients 
(Table 2). The lowest p-value of p = 0.023, using the GENDEP remission GWAS to predict 
remission in STAR*D, did not reach the required Bonferroni correction of 0.0025. 
Secondly, we investigated whether genetic liability to MDD or schizophrenia predicted 
improvement in depressive symptoms, using meta-analyses from the Psychiatric Genomics 
Consortium (PGC) as discovery samples. Seven pharmacogenetic studies (including GENDEP 
and STAR*D) were used as independent target samples (3746 participants). Meta-analysis 
across studies (whole sample or citalopram/escitalopram treated patients) showed no 
predictive ability of genetic li-ability for MDD or for schizophrenia (Fig. 2), with the most 
signiﬁcant result being for schizophrenia PRS at PT b 0.0001 (p = 0.077). Across all PT, PRS 
for MDD showed p-values N 0.1 for the prediction of symptom improvement and regression 
coefﬁcients explained b3% of the variance in symptom improvement. Results by-study at all 
PT values are given in Supplementary Tables 1–2. 
4. Discussion 
In this study, we assessed whether the outcomes of antidepressant treatment may be 
predicted by PRS for (a) improvement and remission from an independent sample, (b) 
genetic liability to MDD, and (c) genetic liability to schizophrenia. Using each of the two 
largest available pharmacogenetic samples on antidepressant response (GENDEP and 
STAR*D) as baseline studies failed to predict antidepressant response in the other study. A 
previous study (GENDEP Investigators, MARS Investigators and STAR฀DInvestigators,2013) 
found a small predicting ability of a PRS calculated in a meta-analysis of GENDEP-MARS 
studies in STAR*D, accounting for about 1.2% of the variance in outcomes in STAR*D. The 
present study was performed using individual datasets as discovery samples but increasing 
the number of genetic variants from ~1.2 million to ~7 million. PRS built from well-powered 
PGC studies for MDD and schizophrenia did not predict symptom improvement, either in 
individual pharmacogenetic studies, or in a meta-analysis. The strongest (non-signiﬁcant) 
polygenic overlap with PGC MDD and schizophrenia data was found for the Pﬁzer 
pharmacogenetic sample (Supplementary Tables 1 and 2). This sample included a higher 
proportion of females and patients with later MDD onset compared to other samples, with a 
shorter trial duration, but we did not have the power to determine how these differences 
may have played a role in the results. A previous analysis of PRS for bipolar disorder did not 
predict antidepressant response in STAR*D and the NEWMEDS studies, so this analysis was 
not repeated here (Tansey et al., 2014). 
 
Table 2 
Prediction of improvement in depression symptoms and remission after 12 weeks of 
antidepressant treatment. Results are shown for the PT threshold attaining the lowest p-
value. R2; Proportion of variance explained. 
 
 
 
 
 
Fig. 2. Meta-analysis of PRS effect sizes (β) in seven pharmacogenetic studies for (1) MDD 
and (2) schizophrenia PRS. Labels show p-values for meta-analyses at each p threshold. 
 
This study represents the largest investigation of the PRS for antidepressant response to 
date, including the majority of currently available pharmacogenetic data on antidepressant 
response in MDD (3746 participants from 7 studies). Both PGC discovery studies were well 
powered. The PGC schizophrenia study identiﬁed a genetic component accounting for 
approximately 7% of the liability to schizophrenia. MDD shares susceptibility genetic factors 
with schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), 
suggesting a possible overlap between the genetics of schizophrenia and antidepressant 
response. The unpublished PGC MDD meta-analysis has a substantially increased sample 
size from the previous study (Ripke et al., 2013b) as well as from the recent MDD GWAS 
from 23andMe (Hyde et al., 2016). MDD PRS comparable to the ones we calculated could 
not be constructed from the 23andme study since only SNPs with p b 10−5 are publicly 
available. 
Despite the extensive resources analysed, the power to detect pre-dictions across study 
using PRS remained low for antidepressant response, although the power was adequate 
when we investigated common genetic liability with MDD and schizophrenia. The modest 
pharmacogenetic study sample sizes also precluded other whole-genome-approaches to 
estimate genetic correlation using GCTA or LD score regression (Yang et al., 2011; 
BulikSullivan et al., 2015). A sample size ten-times larger would be required to achieve 80% 
for polygenic prediction between studies of antidepressant response. National registers and 
electronic medical records of large health care organisations could be used to achieve a 
study of this magnitude, but requires substantial resources for selection of appropriate 
subjects, phenotyping DNA collection, genotyping and analysis. The power to detect 
common liability with psychiatric disorders was higher, but required the assumption of high 
genetic correlation. 
Other limitations of the study arise from the differences in pharmacogenetic studies in 
characteristics of ascertainment, baseline severity, treatment, assessment of outcome and 
length of follow-up. We chose to focus on two largest studies (GENDEP, STAR*D) to test PRS 
for antidepressant response, to avoid adding multiple smaller studies where noise would 
outweigh signal. In the higher powered analysis assessing genet-ic component of MDD and 
schizophrenia, we included all available pharmacogenetic studies. Although there were 
substantial differences in the design of the studies, inclusion criteria were relatively similar 
and it was possible to establish comparable outcome measures. Ethnicity is also a possible 
cause of stratiﬁcation in GWAS despite correction using ancestry-informative principal 
components. Heterogeneity across samples due to ethnicity or other factors may be a 
limitation of the ﬁxed-effects meta-analysis that we carried out. 
We performed a single sub-analysis restricting to participants treated by citalopram or 
escitalopram, since escitalopram is the active isomer of citalopram (N = 2308 participants) 
(Svensson and Mansﬁeld, 2004). These analyses also failed to predict improvement of 
antidepressant symptoms or remission. Many further sub-hypotheses could be tested, for 
example, stratifying by sex, symptom dimensions, age, or severity. Recognising the need to 
balance a larger effect size in one subgroup against the smaller sample size and increased 
correction for multiple testing, we focused on the key hypotheses (Traylor, Markus and 
Lewis, 2015). 
The identiﬁcation of individual genetic associations with antidepressant treatment response 
has been challenging, with no genome-wide studies identifying replicated signals for 
association (Uher et al., 2010; Garriock et al., 2010; Ising et al., 2009). Since no major, single 
locus variants play a major role in treatment response, building polygenic predictors, which 
capture modest effects at multiple SNPs, may be a feasible alternative. STAR*D, GENDEP 
and other NEWMEDS studies show a strong polygenic component to the genetic 
architecture of response to antidepressants, with common genetic variation estimated to 
explain 42% of individual differences (SE = 0.180, p =0.009) (Tansey et al., 2013). With the 
decreasing costs of genotyping, and increasing access to such data, a PRS could form a 
powerful predictor response, and be of clinical value, as already seen in predicting disease 
risk (Chhibber et al., 2014; Chatterjee, Shi and García-Closas, 2016). Other strategies, such as 
machine learning application to clinical and genetic variables in STAR*D and NEWMEDs 
studies showed some prediction based on both genetic and clinical characteristics, which 
was antidepressant speciﬁc(Iniesta et al., 2016). 
We selected here two reasonable polygenic hypotheses that (1) the European Federation of 
Pharmaceutical Industries and Associations (EFPIA) in-kind contribution and ﬁnancial 
contribution from the European Union Seventh Framework Programme (FP7/2007-2013). 
This article represents independent research part funded by the National Institute for 
Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King's College London. The views expressed are those of the authors 
and not necessarily those of the NHS, the NIHR or the Department of Health. 
The funding source had no role in study design, collection, analysis or interpretation of data, 
in the writing of the report or in the decision to submit the article for publication. 
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